GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Microbot Medical Inc (NAS:MBOT) » Definitions » Altman Z2-Score

Microbot Medical (Microbot Medical) Altman Z2-Score : -35.01 (As of Jun. 04, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Microbot Medical Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Microbot Medical has a Altman Z2-Score of -35.01, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Microbot Medical's Altman Z2-Score or its related term are showing as below:

MBOT' s Altman Z2-Score Range Over the Past 10 Years
Min: -636.15   Med: -14.32   Max: 19.88
Current: -35.01

During the past 13 years, Microbot Medical's highest Altman Z2-Score was 19.88. The lowest was -636.15. And the median was -14.32.


Microbot Medical Altman Z2-Score Historical Data

The historical data trend for Microbot Medical's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbot Medical Altman Z2-Score Chart

Microbot Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.05 11.11 -3.56 -24.73 -35.30

Microbot Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.16 -16.85 -25.85 -35.30 -35.01

Competitive Comparison of Microbot Medical's Altman Z2-Score

For the Medical Instruments & Supplies subindustry, Microbot Medical's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbot Medical's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Microbot Medical's Altman Z2-Score falls into.



Microbot Medical Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Microbot Medical's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.7896+3.26*-11.1133+6.72*-1.3924+1.05*5.1392
=-35.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $7.37 Mil.
Total Current Assets was $7.00 Mil.
Total Current Liabilities was $1.18 Mil.
Retained Earnings was $-81.87 Mil.
Pre-Tax Income was -2.371 + -3.154 + -2.446 + -2.287 = $-10.26 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Liabilities was $1.20 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(7 - 1.183)/7.367
=0.7896

X2=Retained Earnings/Total Assets
=-81.872/7.367
=-11.1133

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-10.258 - 0)/7.367
=-1.3924

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(6.167 - 0)/1.2
=5.1392

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Microbot Medical has a Altman Z2-Score of -35.01 indicating it is in Distress Zones.


Microbot Medical  (NAS:MBOT) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Microbot Medical Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Microbot Medical's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbot Medical (Microbot Medical) Business Description

Traded in Other Exchanges
Address
25 Recreation Park Drive, Unit 108, Hingham, MA, USA, 02043
Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.
Executives
Rachel Vaknin officer: Chief Financial Officer DROR 3/10, ZICHRON YAAKOV L3 3090216
Simon Sharon officer: General Manager & CTO 8 HAMADA STREET, ZICHRON YAACOV L3 3090708
Yoseph Bornstein director, 10 percent owner 16 IRUS STREET, ROSH HA'AYIN L3 4858022
Tal Baruch Wenderow director 1149, BEACON STREET, NEWTON MA 02461
Eyal Morag officer: Chief Medical Officer BONEY HAEAR 3 STREET, APT #13, TEL AVIV L3 6937303
Aileen Ptucha Stockburger director 26 WELLINGTON CT, BELLE MEADE NJ 08502
Harel Gadot director, 10 percent owner, officer: Chairman and CEO 5 VILLAGE LANE, HINGHAM MA 02043
Joseph Mona 10 percent owner 808 HAMPTON ST, COLUMBIA SC 29201
Prattipati Laxminarain director 3 HEWINS FARM ROAD, WELLESLEY MA 02481
Yoav Zvi Waizer director 8 HAVERED STREET, RAANANA L3 4352308
Moshe Shoham director 22 BEDOLACH STREET, HOSHAYA L3 1791500
Leon Lewkowicz 10 percent owner GORDON STREET 10, APARTMENT 7, TEL-AVIV L3 63458
Martin J. Madden director C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043
Yehezkel Himelfarb officer: General Manager & COO 32 BEN YOSEF STREET, TEL-AVIV L3 6912530
Sandra Berkson 10 percent owner C/O SABER HOLDING GMBH, WEIN KRUMMBAUMGASSE C4 1020

Microbot Medical (Microbot Medical) Headlines

From GuruFocus